BS, YY, and GK are employees of Amgen and own shares of Amgen.
LK has served either as an investigator, speaker, consultant or advisory board member for Amgen, BMS, Celgene, Novartis, Eli Lilly, BI, Abbvie, Pfizer, Ortho Dermatologic, Leo, Sun, Dermavant, Arcutis, Janssen.
Funding: This study was sponsored by Amgen Inc.
Data Sharing Statement: Qualified researchers may request data from Amgen clinical studies. Complete details are available at the following: https://wwwext.amgen.com/science/clinical-trials/ clinical-data-transparency-practices/
This study was supported by Amgen Inc. Jessica Ma, PhD (Amgen Inc.) and Albert Y. Rhee, PhD (Amgen Inc.) provided manuscript writing support.
2. Schäfer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2010 Jan-Feb;20(1):62-7.
3. Viswanathan HN, Chau D, Milmont CE, Yang W, Erondu N, Revicki DA, Klekotka P. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015 Jun;26(3):235-9.
4. Bagel J, Samad AS, Stolshek BS, Aras GA, Chung JB, Kricorian G, Kircik LH. Open-label study to evaluate the effica-cy of etanercept treatment in subjects with moderate to severe plaque psoriasis who have failed therapy with apre-milast. J Drugs Dermatol. 2018 Oct 1;17(10):1078-1082.
5. Bushnell DM, Martin ML, McCarrier K, Gordon K, Chiou CF, Huang X, Ortmeier B, Kricorian G. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013 Oct;24(5):356-60. 6. Revicki DA, Jin Y, Wilson HD, Chau D, Viswanathan HN. Reliability and validity of the psoriasis symptom inven-tory in patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2014 Feb;25(1):8-14.
7. Bushnell DM, Martin ML, Scanlon M, Chen T, Chau D, Viswanathan HN. Equivalence and measurement properties of an electronic version of the Psoriasis Symptom Inventory. Qual Life Res. 2014 Apr;23(3):897-906.
8. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015 Oct;373(14):1318- 28.
9. Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A. A prospective phase III, randomized, doubleblind, placebo-controlled study of brodalumab in patients with moderate-tosevere plaque psoriasis. Br J Dermatol. 2016 Aug;175(2):273-86.
10. Mease P, Sieper J, Van den Bosch F, Rahman P, Karunaratne PM, Pangan AL. Randomized controlled trial of ada-limumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol. 2015 Apr;67(4):914-23.
11. Feldman SR, Thaçi D, Gooderham M, Augustin M, de la Cruz C, Mallbris L, Buonanno M, Tatulych S, Kaur M, Lan S, Valdez H, Mamolo C. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2017 Mar;176(3):759-764.